{"id":37894,"date":"2017-02-27T08:49:14","date_gmt":"2017-02-27T13:49:14","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=37894"},"modified":"2017-02-27T08:49:14","modified_gmt":"2017-02-27T13:49:14","slug":"therapeuticsmd-inc-nysemkttxmd-expects-to-release-tx-004hr-in-4q2017","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/therapeuticsmd-inc-nysemkttxmd-expects-to-release-tx-004hr-in-4q2017-37894","title":{"rendered":"TherapeuticsMD Inc (NYSEMKT:TXMD) Expects To Release TX-004HR In 4Q2017"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>TherapeuticsMD Inc (NYSEMKT:TXMD)<\/strong> a unique women\u2019s healthcare firm reported fourth quarter and full-year fiscal report for 2016. For the year closed December 2016, net revenue was almost $19.4 million versus almost $20.1 million for the previous year. Net revenue for 4Q2016 was almost $4.5 million as against net revenue of around $5.6 million for the previous year\u2019s quarter. This change can be attributed to a drop in the mean net sales price of their offerings, partially offset by a jump in the number of units offered.<\/p>\n<h2 style=\"text-align: justify;\"><strong>The details<\/strong><\/h2>\n<p style=\"text-align: justify;\">Total operating expenses for 4Q2016 and FY2016 comprised R&amp;D expenses and SG&amp;A. R&amp;D expenses for FY2016 were almost $53.9 million versus around $72 million for the previous year. R&amp;D costs for the 4Q2016 came at around $10.3 million versus close to $13.3 million in the prior year\u2019s quarter.<\/p>\n<p style=\"text-align: justify;\">The decline in R&amp;D can be attributed to lower clinical trial expenses as the firm closed its Phase III clinical studies for TX-001HR and TX-004HR. While SG&amp;A costs for FY2016 came at approximately $51.3 million as against about $28.7 million for the preceding year. SG&amp;A costs for 4Q2016 were about $16.3 million as against around $8.6 million for the previous year\u2019s quarter. The jump in SG&amp;A were mainly due to increased sales, regulatory expenditures, marketing, and personnel costs to boost future commercialization.<\/p>\n<p style=\"text-align: justify;\">Net loss for FY2016 was almost $89.9 million compared with about $85.1 million for the FY2015. While net loss in 4Q2016 was almost $22.8 million compared with about $17.5 million for 4Q2015. As of close of December 2016, cash on hand was almost $131.5 million, as against with almost $64.7 million as of close of December 2015.<\/p>\n<p style=\"text-align: justify;\">In the last trading session, the stock price of jumped more than 3% to close the day at $5.84. After the recent gains, the market cap of firm stands at 1.19 billion.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>TherapeuticsMD Inc (NYSEMKT:TXMD) a unique women\u2019s healthcare firm reported fourth quarter and full-year fiscal report for 2016. For the year closed December 2016, net revenue [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":26313,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[2409,12332,7429],"stock_ticker":[],"class_list":["post-37894","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nysemkttxmd","tag-therapeuticsmd-inc","tag-therapeuticsmd-inc-nysemkttxmd","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>TherapeuticsMD Inc (NYSEMKT:TXMD) Expects To Release TX-004HR In 4Q2017 - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/therapeuticsmd-inc-nysemkttxmd-expects-to-release-tx-004hr-in-4q2017-37894\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TherapeuticsMD Inc (NYSEMKT:TXMD) Expects To Release TX-004HR In 4Q2017 - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"TherapeuticsMD Inc (NYSEMKT:TXMD) a unique women\u2019s healthcare firm reported fourth quarter and full-year fiscal report for 2016. For the year closed December 2016, net revenue [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/therapeuticsmd-inc-nysemkttxmd-expects-to-release-tx-004hr-in-4q2017-37894\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-02-27T13:49:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/TherapeuticsMD-Inc.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"275\" \/>\n\t<meta property=\"og:image:height\" content=\"183\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/therapeuticsmd-inc-nysemkttxmd-expects-to-release-tx-004hr-in-4q2017-37894#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/therapeuticsmd-inc-nysemkttxmd-expects-to-release-tx-004hr-in-4q2017-37894\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"TherapeuticsMD Inc (NYSEMKT:TXMD) Expects To Release TX-004HR In 4Q2017\",\"datePublished\":\"2017-02-27T13:49:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/therapeuticsmd-inc-nysemkttxmd-expects-to-release-tx-004hr-in-4q2017-37894\"},\"wordCount\":316,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/therapeuticsmd-inc-nysemkttxmd-expects-to-release-tx-004hr-in-4q2017-37894#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/TherapeuticsMD-Inc.jpg\",\"keywords\":[\"NYSEMKT:TXMD\",\"TherapeuticsMD Inc\",\"TherapeuticsMD Inc (NYSEMKT:TXMD)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/therapeuticsmd-inc-nysemkttxmd-expects-to-release-tx-004hr-in-4q2017-37894#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/therapeuticsmd-inc-nysemkttxmd-expects-to-release-tx-004hr-in-4q2017-37894\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/therapeuticsmd-inc-nysemkttxmd-expects-to-release-tx-004hr-in-4q2017-37894\",\"name\":\"TherapeuticsMD Inc (NYSEMKT:TXMD) Expects To Release TX-004HR In 4Q2017 - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/therapeuticsmd-inc-nysemkttxmd-expects-to-release-tx-004hr-in-4q2017-37894#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/therapeuticsmd-inc-nysemkttxmd-expects-to-release-tx-004hr-in-4q2017-37894#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/TherapeuticsMD-Inc.jpg\",\"datePublished\":\"2017-02-27T13:49:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/therapeuticsmd-inc-nysemkttxmd-expects-to-release-tx-004hr-in-4q2017-37894#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/therapeuticsmd-inc-nysemkttxmd-expects-to-release-tx-004hr-in-4q2017-37894\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/therapeuticsmd-inc-nysemkttxmd-expects-to-release-tx-004hr-in-4q2017-37894#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/TherapeuticsMD-Inc.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/TherapeuticsMD-Inc.jpg\",\"width\":275,\"height\":183},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/therapeuticsmd-inc-nysemkttxmd-expects-to-release-tx-004hr-in-4q2017-37894#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TherapeuticsMD Inc (NYSEMKT:TXMD) Expects To Release TX-004HR In 4Q2017\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TherapeuticsMD Inc (NYSEMKT:TXMD) Expects To Release TX-004HR In 4Q2017 - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/therapeuticsmd-inc-nysemkttxmd-expects-to-release-tx-004hr-in-4q2017-37894","og_locale":"en_US","og_type":"article","og_title":"TherapeuticsMD Inc (NYSEMKT:TXMD) Expects To Release TX-004HR In 4Q2017 - Wall Street PR","og_description":"TherapeuticsMD Inc (NYSEMKT:TXMD) a unique women\u2019s healthcare firm reported fourth quarter and full-year fiscal report for 2016. For the year closed December 2016, net revenue [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/therapeuticsmd-inc-nysemkttxmd-expects-to-release-tx-004hr-in-4q2017-37894","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2017-02-27T13:49:14+00:00","og_image":[{"width":275,"height":183,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/TherapeuticsMD-Inc.jpg","type":"image\/jpeg"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/therapeuticsmd-inc-nysemkttxmd-expects-to-release-tx-004hr-in-4q2017-37894#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/therapeuticsmd-inc-nysemkttxmd-expects-to-release-tx-004hr-in-4q2017-37894"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"TherapeuticsMD Inc (NYSEMKT:TXMD) Expects To Release TX-004HR In 4Q2017","datePublished":"2017-02-27T13:49:14+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/therapeuticsmd-inc-nysemkttxmd-expects-to-release-tx-004hr-in-4q2017-37894"},"wordCount":316,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/therapeuticsmd-inc-nysemkttxmd-expects-to-release-tx-004hr-in-4q2017-37894#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/TherapeuticsMD-Inc.jpg","keywords":["NYSEMKT:TXMD","TherapeuticsMD Inc","TherapeuticsMD Inc (NYSEMKT:TXMD)"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/therapeuticsmd-inc-nysemkttxmd-expects-to-release-tx-004hr-in-4q2017-37894#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/therapeuticsmd-inc-nysemkttxmd-expects-to-release-tx-004hr-in-4q2017-37894","url":"https:\/\/cablemanpro.com\/wallstreetpr\/therapeuticsmd-inc-nysemkttxmd-expects-to-release-tx-004hr-in-4q2017-37894","name":"TherapeuticsMD Inc (NYSEMKT:TXMD) Expects To Release TX-004HR In 4Q2017 - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/therapeuticsmd-inc-nysemkttxmd-expects-to-release-tx-004hr-in-4q2017-37894#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/therapeuticsmd-inc-nysemkttxmd-expects-to-release-tx-004hr-in-4q2017-37894#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/TherapeuticsMD-Inc.jpg","datePublished":"2017-02-27T13:49:14+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/therapeuticsmd-inc-nysemkttxmd-expects-to-release-tx-004hr-in-4q2017-37894#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/therapeuticsmd-inc-nysemkttxmd-expects-to-release-tx-004hr-in-4q2017-37894"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/therapeuticsmd-inc-nysemkttxmd-expects-to-release-tx-004hr-in-4q2017-37894#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/TherapeuticsMD-Inc.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/TherapeuticsMD-Inc.jpg","width":275,"height":183},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/therapeuticsmd-inc-nysemkttxmd-expects-to-release-tx-004hr-in-4q2017-37894#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"TherapeuticsMD Inc (NYSEMKT:TXMD) Expects To Release TX-004HR In 4Q2017"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/37894","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=37894"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/37894\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/26313"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=37894"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=37894"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=37894"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=37894"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}